Ocugen announce Phase 3 enrolment completion for OCU400, the largest gene agnostic therapy trial for RP
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Search
Search results
Webinar: The Big Give: How your donations make a difference
Join us to find out how your donations make a direct different and fund research.
Look Forward – Autumn 2026 – Issue 191
Thank you to our fabulous 5K a Day in May supporters who raised more than £8,000 this year.
Seeing the light: Scientists use photoswitch drugs to restore vision in animal study
A consortium of researchers based at the Institute for Bioengineering of Catalonia (IBEC) have demonstrated that specially designed light-activated drugs can restore useful visual function in blind animals by making surviving retinal nerve cells respond to light.
Looking after your vision
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
The Gene Team
Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.
Look Forward – Spring 2024 – Issue 182
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
New nanoparticle gene therapy research provides hope for treating inherited sight loss
Researchers from Ghent University have published a study that has the potential to transform inherited retinal disease (IRD) treatment development.
Breakthrough BBS10 treatment marks major milestone
Catherine L’Estrange, aged 11 from London has become the first individual in the UK to receive an investigative gene therapy treatment for retinal dystrophy associated with the BBS10 gene.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.